A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

The invention relates to compositions for use in the treatment or prevention of pathogenic infections, rosacea, eczema and psoriasis in humans or animals. The compositions of the invention are also useful in the healing of wounds in a human or animal, and for killing or inactivating viruses on a surface.

The invention relates to compositions for use in the treatment or prevention of pathogenic infections, rosacea, eczema and psoriasis in humans or animals. The compositions of the invention are also useful in the healing of wounds in a human or animal, and for killing or inactivating viruses on a surface.

Disclosed herein are combinations that include one or more conjugated oligoelectrolyte compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, and one or more antibiotics. Combination of one or more conjugated oligoelectrolyte compounds and one or more antibiotics can potentiate the activity of the one or more antibiotics. Also disclosed are methods treating, reducing the severity of and/or slowing the progression of a bacterial infection, such as Gram-positive and Gram-negative bacteria, using a combination described herein.

Disclosed herein are combinations that include one or more conjugated oligoelectrolyte compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, and one or more antibiotics. Combination of one or more conjugated oligoelectrolyte compounds and one or more antibiotics can potentiate the activity of the one or more antibiotics. Also disclosed are methods treating, reducing the severity of and/or slowing the progression of a bacterial infection, such as Gram-positive and Gram-negative bacteria, using a combination described herein.

Provided herein are compositions of lipid-based nanoparticles, such as exosomes, that contain a therapeutic STAT3-targeting inhibitory RNA. Also provided are methods of using such compositions to treat a patient having fibrosis or a disease associated with fibrosis.

Provided herein are compositions of lipid-based nanoparticles, such as exosomes, that contain a therapeutic STAT3-targeting inhibitory RNA. Also provided are methods of using such compositions to treat a patient having fibrosis or a disease associated with fibrosis.

The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.